Bone continuum of cancer

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Many patients with solid tumors, especially breast and prostate cancers, and with multiple myeloma will develop bone metastases or other skeletal complications. The management of bone loss and symptomatic bone metastases is an important issue in the care and maintenance of quality of life for these patients. Morbidity caused by skeletal complications include pain (bone metastases are known as the most common cause of cancer-related pain), hypercalcemia, pathologic fracture, compression of the spinal cord or cauda equine, and spinal instability. Currently, the only Food and Drug Administration-approved therapy for metastatic bone disease is bisphosphonate therapy. A greater understanding of the biomolecular pathways that govern the bone continuum of cancer has helped identify novel targets for drug development. New therapeutic options are currently being investigated for the treatments of bone loss and symptomatic bone metastases. Some of these new drugs and modalities are in advanced stages of clinical development and may soon reach the clinic.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number3 SUPPL.
DOIs
StatePublished - Jun 1 2010

Fingerprint

Bone Neoplasms
Bone and Bones
Neoplasm Metastasis
Spontaneous Fractures
Spinal Cord Compression
Bone Diseases
Diphosphonates
Hypercalcemia
United States Food and Drug Administration
Therapeutics
Multiple Myeloma
Pharmaceutical Preparations
Horses
Prostatic Neoplasms
Quality of Life
Breast Neoplasms
Morbidity
Pain
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{31f62f366d0243c8967bbe5be2cc1155,
title = "Bone continuum of cancer",
abstract = "Many patients with solid tumors, especially breast and prostate cancers, and with multiple myeloma will develop bone metastases or other skeletal complications. The management of bone loss and symptomatic bone metastases is an important issue in the care and maintenance of quality of life for these patients. Morbidity caused by skeletal complications include pain (bone metastases are known as the most common cause of cancer-related pain), hypercalcemia, pathologic fracture, compression of the spinal cord or cauda equine, and spinal instability. Currently, the only Food and Drug Administration-approved therapy for metastatic bone disease is bisphosphonate therapy. A greater understanding of the biomolecular pathways that govern the bone continuum of cancer has helped identify novel targets for drug development. New therapeutic options are currently being investigated for the treatments of bone loss and symptomatic bone metastases. Some of these new drugs and modalities are in advanced stages of clinical development and may soon reach the clinic.",
author = "Allan Lipton",
year = "2010",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e3181deb9e5",
language = "English (US)",
volume = "33",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3 SUPPL.",

}

Bone continuum of cancer. / Lipton, Allan.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 3 SUPPL., 01.06.2010.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bone continuum of cancer

AU - Lipton, Allan

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Many patients with solid tumors, especially breast and prostate cancers, and with multiple myeloma will develop bone metastases or other skeletal complications. The management of bone loss and symptomatic bone metastases is an important issue in the care and maintenance of quality of life for these patients. Morbidity caused by skeletal complications include pain (bone metastases are known as the most common cause of cancer-related pain), hypercalcemia, pathologic fracture, compression of the spinal cord or cauda equine, and spinal instability. Currently, the only Food and Drug Administration-approved therapy for metastatic bone disease is bisphosphonate therapy. A greater understanding of the biomolecular pathways that govern the bone continuum of cancer has helped identify novel targets for drug development. New therapeutic options are currently being investigated for the treatments of bone loss and symptomatic bone metastases. Some of these new drugs and modalities are in advanced stages of clinical development and may soon reach the clinic.

AB - Many patients with solid tumors, especially breast and prostate cancers, and with multiple myeloma will develop bone metastases or other skeletal complications. The management of bone loss and symptomatic bone metastases is an important issue in the care and maintenance of quality of life for these patients. Morbidity caused by skeletal complications include pain (bone metastases are known as the most common cause of cancer-related pain), hypercalcemia, pathologic fracture, compression of the spinal cord or cauda equine, and spinal instability. Currently, the only Food and Drug Administration-approved therapy for metastatic bone disease is bisphosphonate therapy. A greater understanding of the biomolecular pathways that govern the bone continuum of cancer has helped identify novel targets for drug development. New therapeutic options are currently being investigated for the treatments of bone loss and symptomatic bone metastases. Some of these new drugs and modalities are in advanced stages of clinical development and may soon reach the clinic.

UR - http://www.scopus.com/inward/record.url?scp=77953342702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953342702&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181deb9e5

DO - 10.1097/COC.0b013e3181deb9e5

M3 - Review article

VL - 33

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3 SUPPL.

ER -